Precigen, Inc. (PGEN): Price and Financial Metrics

Precigen, Inc. (PGEN): $1.33

0.09 (+7.26%)

POWR Rating

Component Grades













Add PGEN to Watchlist
Sign Up

Industry: Biotech



in industry


  • Momentum is the dimension where PGEN ranks best; there it ranks ahead of 62.7% of US stocks.
  • The strongest trend for PGEN is in Quality, which has been heading down over the past 179 days.
  • PGEN's current lowest rank is in the Value metric (where it is better than 8.25% of US stocks).

PGEN Stock Summary

  • Revenue growth over the past 12 months for Precigen Inc comes in at 0.67%, a number that bests only 19.21% of the US stocks we're tracking.
  • The volatility of Precigen Inc's share price is greater than that of 90.01% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PGEN comes in at -27.37% -- higher than that of only 14.41% of stocks in our set.
  • Stocks that are quantitatively similar to PGEN, based on their financial statements, market capitalization, and price volatility, are IRWD, GKOS, PROG, IPWR, and TMDX.
  • Visit PGEN's SEC page to see the company's official filings. To visit the company's web site, go to

PGEN Valuation Summary

  • PGEN's price/earnings ratio is -11.5; this is 131.51% lower than that of the median Healthcare stock.
  • PGEN's price/sales ratio has moved down 2887.8 over the prior 98 months.
  • PGEN's price/sales ratio has moved down 2887.8 over the prior 98 months.

Below are key valuation metrics over time for PGEN.

Stock Date P/S P/B P/E EV/EBIT
PGEN 2021-08-31 12.4 7.9 -11.5 -15.6
PGEN 2021-08-30 12.2 7.7 -11.3 -15.3
PGEN 2021-08-27 12.3 7.8 -11.4 -15.5
PGEN 2021-08-26 12.1 7.7 -11.2 -15.2
PGEN 2021-08-25 11.9 7.5 -11.0 -15.0
PGEN 2021-08-24 11.9 7.6 -11.1 -15.1

PGEN Growth Metrics

    Its 2 year price growth rate is now at -82.67%.
  • The 5 year net income to common stockholders growth rate now stands at -80.44%.
  • Its 4 year net income to common stockholders growth rate is now at -80.44%.
Over the past 70 months, PGEN's revenue has gone down $79,321,000.

The table below shows PGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 103.873 -55.771 -92.166
2021-09-30 98.985 -57.651 -108.793
2021-06-30 101.007 -59.633 -108.537
2021-03-31 97.851 -65.662 -131.841
2020-12-31 103.178 -77.021 -170.521
2020-09-30 92.203 -92.694 -298.075

PGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PGEN has a Quality Grade of C, ranking ahead of 33.59% of graded US stocks.
  • PGEN's asset turnover comes in at 0.277 -- ranking 449th of 561 Business Services stocks.
  • V, GOVX, and CELP are the stocks whose asset turnover ratios are most correlated with PGEN.

The table below shows PGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.277 0.456 -0.241
2021-03-31 0.276 0.439 -0.310
2020-12-31 0.291 0.462 -0.418
2020-09-30 0.237 0.398 -0.717
2020-06-30 0.201 0.376 -0.731
2020-03-31 0.183 0.387 -0.659

PGEN Price Target

For more insight on analysts targets of PGEN, see our PGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.00 Average Broker Recommendation 1.5 (Moderate Buy)

PGEN Stock Price Chart Interactive Chart >

Price chart for PGEN

PGEN Price/Volume Stats

Current price $1.33 52-week high $8.72
Prev. close $1.24 52-week low $1.12
Day low $1.23 Volume 1,268,328
Day high $1.36 Avg. volume 1,558,273
50-day MA $1.69 Dividend yield N/A
200-day MA $3.45 Market Cap 276.23M

Precigen, Inc. (PGEN) Company Bio

Precigen, Inc. (formerly Intrexon Corporation) provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. The company was founded in 1998 and is based in Germantown, Maryland.

PGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

PGEN Latest Social Stream

Loading social stream, please wait...

View Full PGEN Social Stream

Latest PGEN News From Around the Web

Below are the latest news stories about Precigen Inc that investors may wish to consider to help them evaluate PGEN as an investment opportunity.

H.C. Wainwright Thinks Precigen’s Stock is Going to Recover

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $2.16, close to its 52-week low of $1.91. According to, Ramakanth is a 4-star analyst with an average return of 11.0% and a 39.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Cellectar Biosciences, Harpoon Therapeutics, and Corcept Therapeutics. Currently, the analyst consensus on Precigen is a Strong Buy with an average price target of $13.33, a 522.9% upside from current levels.

Howard Kim on TipRanks | March 2, 2022

Analysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Precigen (PGEN) and BioCardia (BCDA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cassava Sciences (SAVA – Research Report), Precigen (PGEN – Research Report) and BioCardia (BCDA – Research Report) with bullish sentiments. Cassava Sciences (SAVA) In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Cassava Sciences, with a price target of $180.00. The company's shares closed last Tuesday at $40.97, close to its 52-week low of $31.44. According to TipRanks.

Howard Kim on TipRanks | March 1, 2022

Precigen GAAP EPS of -$0.13 beats by $0.01, revenue of $24.22M beats by $1.98M

Precigen press release (PGEN): Q4 GAAP EPS of -$0.13 beats by $0.01.Revenue of $24.22M (+25.3% Y/Y) beats by $1.98M.Cash, cash equivalents, and short-term and long-term…

Seeking Alpha | March 1, 2022

Precigen Reports Fourth Quarter and Full Year 2021 Financial Results

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results.

Yahoo | March 1, 2022

Further weakness as Precigen (NASDAQ:PGEN) drops 10% this week, taking five-year losses to 88%

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...

Yahoo | February 2, 2022

Read More 'PGEN' Stories Here

PGEN Price Returns

1-mo -8.28%
3-mo -39.82%
6-mo -65.54%
1-year -80.18%
3-year -71.64%
5-year -93.92%
YTD -64.15%
2021 -63.63%
2020 86.13%
2019 -16.21%
2018 -43.23%
2017 -52.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6342 seconds.